Generic Drugmaking Firms Fall Short for Poorest Patients
- Analysis examined 50 medicines from five large manufacturers
- Some essential drugs still inaccessible despite price declines
This article is for subscribers only.
Efforts by major generic drugmakers to expand access to essential medicines have fallen short for many of the world’s poorest patients, a new study found.
Only one of out 50 products made by five large generic drug makers — Cipla Ltd., Hikma Pharmaceuticals Plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and Viatris Inc. — had a pricing strategy that took into account a patient’s ability to pay in low-to-middle income nations, according the report from the Access to Medicine Foundation.